Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor β-1 in papillary carcinoma and follicular carcinoma of thyroid

Chinese Journal of Pathology

Volumn 38, Issue 12, 2009, Pages 824-828

  Wang, Ting ^a   Jiang, Chang Xin ^a   Li, Ying ^a   Liu, Xin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Adenocarcinoma follicular; Adenocarcinoma, papillary carcinoma; Thyroid neoplasms

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; CANCER INVASION; CELL DIFFERENTIATION; HUMAN; LYMPH NODE METASTASIS; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 74749107440     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0529-5807.2009.12.009     Document Type: Article

References (17)

1. DeLellis RA, Lloyd RV, Heitz PV, et al. World Health Organization classification of tumours. Pathology and genetics tumours of endocrine organs. Lyon: IARC Press, 2004:51-80.
2. Masi L, Malentacchi C, Campanacci D, et al. Transforming growth factor-β isoform and receptor expression in chondrosarcoma of bone. Virchows Arch, 2002, 440(5):491-497.
3. Pelizzo MR, Merante BI, Toniato A, et al. Diagnosis, treatment, prognostic factors and long-term outcome in papillary thyroid carcinoma. Minerva Endocrinol, 2008, 33(4):359-379.
4. Chinese source
5. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer, 2003, 89(10):1817-1821.
6. Fan SQ, Wei QY, Li MR, et al. Expression and clinical significance of MMP-2, MMP-9, TIMP-1 and MMP-2 in breast carcinoma. Cancer, 2003, 22(9):968-973.
7. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res, 1999, 59(2):467-473.
8. Kraiem Z, Korem S. Matrix metalloproteinases and the thyroid. Thyroid, 2000, 10(12):1061-1069.
9. Khasigov PZ, Podobed OV, Gracheva T, et al. Role of matrix metalloproteinases and their inhibitors in tumor invasion and metastasis. Biochemistry (Mosc), 2003, 68(7):711-717.
10. Fenton C, Patel A, Dinauer C, et al. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth receptor correlate with the size of papiUary thyroid carcinoma in children and young adults. Thyroid, 2000, 10(4):349-357.
11. Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol, 2002, 53(3):129-132.
12. Klein M, Catargi B. VEGF in physiological process and thyroid disease. Ann Endocrinol (Paris), 2007, 68(6):438-448.
13. Lin JD, Chao TC. Vascular endothelial growth factor in thyroid cancers. Cancer Biother Radiopharm, 2005, 20(6):648-661.
14. Younes MN, Yazici YD, Kims S, et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res, 2006, 12(11 Pt 1):3425-3434.
15. Matsuo SE, Leoni SC, Colquhoun A, et al. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol, 2006, 190(1):141-150.
16. Nicolussi A, D'Inzeo S, Santuui M, et al. TGF-beta control of rat thyroid follicular cells differentiation. Mol Cell Endocrinol, 2003, 207(1-2):1-11.
17. Riedel F, Gotte K, Schwalb J, et al. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol, 2000, 17(6):1099-1105.